Peptides & the FDA review: your questions, answered

Epitalon is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal did not place it on the approved list.^{1 2 3}

The evidence is old, small, and mixed. The best-designed human trial, in 1992, found only weak effects and concluded short-term DSIP was unlikely to be of major therapeutic benefit.⁴

'Emideltide' is the name used for the substance in the FDA's 2026 compounding review paperwork; it refers to the same delta sleep-inducing peptide.⁵

DSIP is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee, where it is listed as 'Emideltide.' Removal did not place it on the approved list.^{5 6 7}

Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.^{8 9}

No completed human clinical trials exist. The evidence is from cell and animal studies; safety and effectiveness in people are unknown.¹⁰

DiHexa is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.^{9 8}

No. Removal from Category 2 in April 2026 did not add BPC-157 to the approved Category 1 list. It moved the peptide into a review process, not into approval.^{11 12}

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews seven peptides, hears presentations and public comment, and votes a recommendation on whether each should be added to the 503A bulks list. The vote is advisory; the FDA makes the final call afterward.¹³

No. BPC-157 has not been approved by the FDA for any medical use, and most of the published research is from animal studies rather than large human trials.¹⁴